Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8671 to 8685 of 9079 results

  1. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-HTG10892 Expected publication date: TBC

    HealthTech guidance
    In development

  7. Surgical vessel sealing systems (MT798)

    Discontinued Reference number: GID-HTG10894

    HealthTech guidance
    Discontinued

  8. Zio XT for detecting cardiac arrhythmias

    In development Reference number: GID-HTG10895 Expected publication date: TBC

    HealthTech guidance
    In development

  9. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    Discontinued Reference number: GID-HTG10896

    HealthTech guidance
    Discontinued

  10. Non-invasive skin closure devices for surgical incisions (MT775)

    Discontinued Reference number: GID-HTG10897

    HealthTech guidance
    Discontinued

  11. Benralizumab for previously treated severe nasal polyps [ID1659]

    Discontinued Reference number: GID-TA10818

    Technology appraisal guidance
    Discontinued

  12. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  13. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]

    In development Reference number: GID-TA11640 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    In development Reference number: GID-TA11670 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Iptacopan for treating primary IgA nephropathy [ID6640]

    In development Reference number: GID-TA11844 Expected publication date: TBC

    Technology appraisal guidance
    In development